Skip to main content

Day: July 11, 2024

AMERICAN SALARS MAKES NEW LITHIUM DISCOVERY WITH GRADES UP TO 180 PPM AT ITS BLACK ROCK SOUTH PROJECT, NEVADA

VANCOUVER, BC, July 11, 2024 (GLOBE NEWSWIRE) — AMERICAN SALARS LITHIUM INC. (“AMERICAN SALARS” OR THE “COMPANY”) (CSE: USLI, OTC: ASALF, FWB: Z3P, WKN: A3E2NY) announces it has received the assay results from ALS Geochemistry Laboratory in Reno Nevada (“ALS”) from soil samples collected at the Black Rock South lithium brine project, located 72 Miles North of the Tesla Gigafactory in Nevada. Samples were processed using Boyd RSD rotary crushers and splitter with a 180-micron (80 mesh) sieve, aqua regia digestion, and 41 multi-element ICP-AES analysis (code ME-ICP41). Highlights Out of the 38 soil samples, 33 recorded lithium concentrations of 100 ppm or higher with the highest sample recording 180.5 ppm lithium with an average grade of the 33 samples of 131 ppm across the surface of the property. Anomalous...

Continue reading

Indegene Announces Strategic Collaboration with Microsoft to Help Life Sciences Companies Scale Up Generative AI Adoption and Accelerate Business Impact

PRINCETON, N.J. and BENGALURU, India, July 11, 2024 (GLOBE NEWSWIRE) — Indegene today announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purpose-built, enterprise-grade Generative AI (GenAI) services, thereby driving faster innovation at scale. Indegene and Microsoft have committed to developing resources in highly specialized and skilled medical and technology tools to co-innovate generative AI services and workflows across commercial, medical, regulatory, and clinical functions. “GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain. Using GenAI, we’re closely working with many of our clients to solve specific business...

Continue reading

Stolt-Nielsen Limited Reports Unaudited Results For the Second Quarter and First Half of 2024

LONDON, July 11, 2024 – Stolt-Nielsen Limited (Oslo Børs ticker: SNI) today reported unaudited results for the second quarter and first half ending May 31, 2024. The Company reported a second-quarter net profit of $100.2 million with revenue of $741.1 million, compared with a net profit of $8.3 million with revenue of $721.9 million in the second quarter of 2023 when the Company recorded a loss provision of $155 million ($115.0 million after tax) related to the MSC Flaminia loss provision. The net profit for the first six months of 2024 was $204.1 million with revenue of $1,448.5 million, compared with a net profit of $108.1 million (net of the MSC Flaminia loss provision of $115.0 million after tax), with revenue of $1,430.6 million, in the first six months of 2023. Highlights for the second quarter of 2024, compared with the second...

Continue reading

Tryg A/S – Q2 and H1 report 2024

  Tryg’s Supervisory Board has today approved the Q2 and H1 2024 interim report. Tryg reported an insurance service result of DKK 2,212m (DKK 1,759m) and a combined ratio of 76.8 (80.9) in Q2 2024, supported by a solid growth in the Private & Commercial segments and a positive underlying performance. The insurance service result was helped by a benign large claims experience against a highly unfavorable one in the corresponding period in 2023. The underlying claims ratio for the Group improved by 40 basis points, whilst the Private segment displayed a deterioration of 40 basis points driven by, as expected, a higher motor claims frequency and a higher average claims cost. Tryg reported a top-line growth of 3.9% mainly driven by price adjustments across all segments to offset inflationary pressure, whilst there was a continued and...

Continue reading

KPN nominates Rob Shuter to Supervisory Board

KPN’s Supervisory Board is pleased to announce the nomination of Mr Rob Shuter for appointment to the Supervisory Board. Rob Shuter (56) is a seasoned executive who has spent his career in the telecommunications and financial services industries. He was CEO Enterprise at BT between 2021 and 2023, Group CEO of MTN Group (South Africa) from 2017 to 2020, CEO of Vodafone Europe (2015-2016) and Vodafone Netherlands (2012-2016) and CFO of Vodacom South Africa (2009-2011). Prior to that, Mr. Shuter spent several years in executive roles in the financial services industry. Currently Shuter serves as a non-executive director of Drax Group Plc, Sir Fruit (Pty) Ltd and is member of the board of trustees of the Duke of Edinburgh’s Award. Mr. Shuter holds British and South African nationality. With his extensive track record in several telecom...

Continue reading

Change in QPR Software Plc’s Management: CFO Mervi Kerkelä-Hiltunen leaves the company

QPR SOFTWARE PLC                   STOCK EXCHANGE RELEASE       11 July 2024 at 9:00 AM EET  QPR Software Plc’s CFO Mervi Kerkelä-Hiltunen has resigned and will continue her career outside the company. Kerkelä-Hiltunen will remain as CFO of QPR Software until early October 2024. The company will immediately initiate the process to appoint Kerkelä-Hiltunen’s successor.  “I want to thank Mervi for her dedication and valuable contribution. Under her leadership, the finance function has crucially supported our company’s turnaround and development. I wish Mervi success in her new endeavors,” said QPR Software Plc’s CEO Heikki Veijola.  For further information:  Heikki Veijola  Chief Executive Officer  QPR Software Plc  Tel. +358 40 922 6029  QPR Software in Brief  QPR Software (Nasdaq Helsinki) is a...

Continue reading

Huhtamaki publishes 2024 Half-yearly Report on July 25, 2024

HUHTAMÄKI OYJ PRESS RELEASE 11.7.2024 AT 09:00 EEST Huhtamäki Oyj will publish its 2024 Half-yearly Report on Thursday, July 25, 2024 at approximately 8:30 (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Huhtamaki will arrange a combined audiocast and teleconference on the same day at 9:30 EEST. Huhtamaki’s CEO & President Charles Héaulmé and CFO Thomas Geust will present the results, followed by a Q&A session. The event will be held in English and it can be followed in real-time. A link to the audiocast is available at: https://huhtamaki.videosync.fi/q2-2024/ A link to the teleconference is available at: https://palvelu.flik.fi/teleconference/?id=50048358. Registration is required for the teleconference. After the registration you will be provided...

Continue reading

Nokia to publish second-quarter and half-year financial report on 18 July 2024

Press Release Nokia to publish second-quarter and half-year financial report on 18 July 2024 11 July 2024Espoo, Finland – Nokia will publish its second-quarter and half-year financial report on 18 July 2024 at approximately 8 a.m. Finnish time (EEST). The report will be made available on the Nokia website immediately after publication. Nokia only publishes a summary of its financial reports in stock exchange releases. The summary focuses on Nokia Group’s financial information as well as on Nokia’s outlook. The detailed, segment-level discussion will be available in the complete financial report hosted at www.nokia.com/financials. A video interview summarizing the key points of our Q2 results will also be published on the website. Investors should not solely rely on summaries of Nokia’s financial reports, but should also...

Continue reading

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified through the application of Foreseen’s proprietary proteomic platforms FS001 has demonstrated robust preclinical efficacy in multiple tumor models and exhibits a favorable preclinical safety profile PARIS, FRANCE, 11 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.